Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 3/20 | 0.46 |
| ▸ | MMP9 | P14780 | 3/20 | 0.46 |
| ▸ | MMP8 | P22894 | 3/20 | 0.46 |
| ▸ | MMP13 | P45452 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3043645 | 0.91 | LTA4H (0.63) | KCNJ1KCNH2MAPTNPC1RAB9A | |
| SCHEMBL4649622 | 0.80 | NPC1 (0.57) | KCNJ1KCNH2MAPTNPC1RAB9A | |
| SCHEMBL722557 | 0.80 | LTA4H (0.64) | KCNJ1KCNH2NOTUMLTA4H | |
| SCHEMBL14988101 | 0.78 | KCNJ1 (0.46) | KCNJ1KCNH2MAPTRAB9AMEN1 | |
| SCHEMBL28810936 | 0.78 | KCNJ1 (0.46) | KCNJ1KCNH2MAPTNPC1RAB9A | |
| SCHEMBL28362996 | 0.78 | LTA4H (0.62) | KCNJ1KCNH2LTA4H | |
| SCHEMBL28320605 | 0.78 | LTA4H (0.62) | KCNJ1KCNH2LTA4H | |
| SCHEMBL28257875 | 0.78 | LTA4H (0.62) | KCNJ1KCNH2LTA4H | |
| SCHEMBL29033804 | 0.76 | KCNJ1 (0.44) | KCNJ1KCNH2MAPTNPC1RAB9A | |
| SCHEMBL16412236 | 0.76 | KCNJ1 (0.44) | KCNJ1KCNH2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732534-B2 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION (JP) | 2010-06-08 | — | — | US | claimed |
| US-20080051552-A1 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION | 2008-02-28 | — | — | US | claimed |
| US-20080051519-A1 | Polymers functionalized with nitro compounds | BRIDGESTONE CORPORATION (JP) | 2008-02-28 | — | — | US | claimed |
| US-12559495-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-02-24 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| CN-109776537-B | Purine diones as WNT pathway modulators | 新加坡科技研究局 | 2021-12-14 | — | — | CN | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-11-24 | — | — | US | disclosed |
| US-20200190086-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-18 | — | — | US | disclosed |
| EP-2999699-B1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY SCIENCE TECH & RES (SG) | 2020-04-29 | — | — | EP | disclosed |
| US-6096144-A | TREATING WITH ACIDIC OR ALKALINE SOLUTION OF CONJUGATED UNSATURATED COMPOUND WITH AT LEAST 5 BONDS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5858571-A | TREATING A PULVERIZED HYDROGEN ABSORBING ALLOY WITH A SOLUTION COMPRISING A CONJUGATED UNSATURATED COMPOUND | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1999-01-12 | — | — | US | disclosed |
| EP-0872903-A1 | Method for making hydrogen storage alloy powder and electrode comprising the alloy powder | Shin-Etsu Chemical Co., Ltd. (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5770615-A | Catecholamine surrogates useful as β3 agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1997037646-A1 | CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-16 | — | — | WO | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | KCNJ1 3173/4885KCNH2 2919/4885MAPT 4782/4885 |
| US-20200190086-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, CTNNB1 | KCNJ1 2611/4885KCNH2 2512/4885MAPT 4783/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | KCNJ1 3173/4885KCNH2 2919/4885MAPT 4782/4885 |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | KCNJ1 2611/4885KCNH2 2512/4885MAPT 4783/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | KCNJ1 3173/4885KCNH2 2919/4885MAPT 4782/4885 |
| US-12559495-B2 | Purine diones as Wnt pathway modulators | WNT1, CTNND1, WNT3A | KCNJ1 474/4885KCNH2 692/4885MAPT 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.